Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1Phase 1/2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 126Melanoma 92Neoplasms 82Colorectal Neoplasms 62Squamous Cell Carcinoma of Head and Neck 61Neoplasm Metastasis 59Triple Negative Breast Neoplasms 51Carcinoma, Renal Cell 47Breast Neoplasms 39Lung Neoplasms 37Ovarian Neoplasms 32Pancreatic Neoplasms 30Head and Neck Neoplasms 29Stomach Neoplasms 28Urinary Bladder Neoplasms 26Carcinoma, Transitional Cell 26Endometrial Neoplasms 24Parkinson Disease 4, Autosomal Dominant Lewy Body 23Uterine Cervical Neoplasms 21Carcinoma, Hepatocellular 18Recurrence 15Esophageal Neoplasms 15Prostatic Neoplasms 14Lymphoma 14Small Cell Lung Carcinoma 12Carcinoma, Squamous Cell 12Kidney Neoplasms 11Cholangiocarcinoma 11Advanced Solid Tumor 11Solid Tumor 10

Interventions

Gemcitabine 4pembrolizumab 3Docetaxel 3aflibercept 2Trastuzumab 2Specimen Handling 2Cisplatin 2Carboplatin 2vinflunine 1tipifarnib 1erdafitinib 1enzalutamide 1entinostat 1enfortumab vedotin 1cabozantinib 1avelumab 1Thalidomide 1Sorafenib 1Ramucirumab 1Radiotherapy 1Platinum 1Nivolumab 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Ipilimumab 1Introns 1Interleukin-12 Subunit p35 1Interleukin-12 1Interferon-alpha 1Interferon alpha-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Urethral Neoplasms × pembrolizumab × Clear all
NCT03582475 2025-11-12

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Jonsson Comprehensive Cancer Center

Phase 1 Active not recruiting
15 enrolled 17 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Prostatic Neoplasms, Urethral Neoplasms

NCT02443324 2024-07-31

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Eli Lilly and Company

Phase 1 Completed
175 enrolled 23 charts
GastrointestinalGenitourinaryThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT02437370 2022-10-18

Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer

University of California, Davis

Phase 1 Completed
32 enrolled
Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡